載入...
Afatinib for the treatment of metastatic non-small cell lung cancer
Targeting the epidermal growth factor receptor (EGFR) in patients with non-small cell lung cancer (NSCLC) harboring sensitizing mutations in the tyrosine kinase (TKI) domain has led to a significant change in the management of this disease. The classic or sensitizing mutations are G719X mutation in...
Na minha lista:
| 發表在: | Cancer Manag Res |
|---|---|
| Main Authors: | , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Dove Medical Press
2015
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4340466/ https://ncbi.nlm.nih.gov/pubmed/25733926 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S51808 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|